Repair and pain
Does it heal a tendon faster?
The claim BPC-157 is sold on. Check how much of the evidence under it was measured in a person rather than a rat.
0
people in trials
0
human studies
3
compounds, animal or cell only
0
trials found nothing
No trial in people
Nobody has run a controlled trial in people for tendon, ligament and injury healing on anything in this archive.
That is a statement about the trial record, and it is not the same as a negative result. Nothing here has been tested and failed. The question is open, and the rest of this page is what does exist: the animal and cell work, what people using these compounds report, and the reason the human trial was never run.
Measured in animals or cells, not yet in people
These are separated from the trials above rather than ranked against them, because they answer a different question. A result in a rat is a real result and a reason somebody ran the study; it is not a measurement of what happens in you. Where the human work is missing, the reason is usually money rather than failure, and that is set out at the bottom of this page.
- 1 preclinical study
Measured in animals or cells
In rats with transected Achilles tendon, daily BPC 157 improved biomechanical load to failure, functional index scores and collagen formation versus saline.
What people using it report
- The injuries people describe treating are tendinopathy, especially elbow, shoulder and Achilles, partial muscle tears, knee pain and post-surgical recovery, plus gut complaints such as reflux and inflammatory bowel symptoms.
- Reported timelines are typically a reduction in pain in the first one to two weeks and a change in what the joint or tendon tolerates by weeks three to six. People who stop before about four weeks commonly report no lasting change.
- Reports of new or worsening tendon or joint discomfort during use exist but are much less common than reports of relief, and no published study has looked for them systematically.
- 1 preclinical study
Measured in animals or cells
Mouse. Using the p16-3MR transgenic model after anterior cruciate ligament transection, selective elimination of senescent cells attenuated post-traumatic osteoarthritis, reduced pain and increased cartilage development, reproduced by intra-articular injection of a senolytic molecule in transgenic, non-transgenic and aged mice. Cells from patients undergoing knee replacement were treated in culture, not in the patients.
Nature Medicine, 2017 · animal
- 1 preclinical study
Measured in animals or cells
Human periodontal ligament stem cells exposed to AED, KED, Lys-Glu and AEDG. The combination of all four peptides and KED alone raised GAP-43 and nestin expression. Notably the effect the authors highlight is for KED and for the mixture, not for AED on its own, and the setting is cell culture.
International Journal of Immunopathology and Pharmacology, 2019 · in vitro
What people using these actually report
Uncontrolled self-reports, gathered from clinic write-ups, regulatory complaint records and public forums, and reproduced here as written. They are the best guide on this page to what people actually do, what they expect, and what goes wrong, and they cannot show that anything works, because nobody was measured against a placebo and the people who saw no effect mostly stopped posting. Both halves of that are true at once. The negative reports are kept in for the same reason.
- The injuries people describe treating are tendinopathy, especially elbow, shoulder and Achilles, partial muscle tears, knee pain and post-surgical recovery, plus gut complaints such as reflux and inflammatory bowel symptoms.
- Reported timelines are typically a reduction in pain in the first one to two weeks and a change in what the joint or tendon tolerates by weeks three to six. People who stop before about four weeks commonly report no lasting change.
- Reports of new or worsening tendon or joint discomfort during use exist but are much less common than reports of relief, and no published study has looked for them systematically.
Sources: FDA's July 2026 evaluation of BPC-157, which reproduces the FAERS adverse event reports through December 4, 2025, the Human Foods Program complaint records, and the marketed dosage forms and strengths; the three published clinic reports above, which are the only documented clinical practice; the 2025 HSS Journal systematic review and the 2026 American Journal of Sports Medicine and Sports Medicine reviews, which describe how athletes and clinicians are using these peptides and note that indications, dosing, frequency and duration all remain undefined; and public injury logs and question threads on peptide and bodybuilding forums including eroids, iSARMS, Ironsport and FITMISC. Reddit's r/Peptides and r/PeptideSupport could not be retrieved for this entry, so nothing above is attributed to any specific post, and no quotation is reproduced from any of these sources.
- The uses people report are chronic tendon and ligament complaints, shoulder and hip problems, scar tissue and range of motion, and general recovery between hard training blocks.
Sources: FDA's July 2026 evaluation of TB-500, including its FAERS search, its catalogue of vendor claims and its account of the veterinary preparation; the 2012 Ghent doping-control identification paper; the 2026 Sports Medicine and American Journal of Sports Medicine reviews on how these peptides are used and marketed; and public discussion and injury logs on peptide and bodybuilding forums including eroids, iSARMS, Ironsport and FITMISC, where TB-500 is almost always logged alongside BPC-157. Reddit's r/Peptides and r/PeptideSupport could not be retrieved for this entry. No quotation is reproduced from any of these sources and nothing above is attributed to a specific person.
- Reduced joint and tendon pain in the first few weeks, described in the same terms people use for BPC-157 on its own.
Sources: Peptide and bodybuilding forums including r/peptides, clinic write-ups and vendor testimonial pages. These are uncontrolled self-reports, usually from people running other things at the same time, frequently including a topical copper serum. They are recorded here as reports and are not evidence of effect. The FDA adverse event material referenced above comes from the agency's 2026 BPC-157 evaluation cited on this page.
- Nagging tendon or joint pain easing, described in the same terms used for BPC-157 alone.
Sources: Peptide and skincare forums including r/peptides, clinic write-ups and vendor testimonial pages. No trial of this blend exists, so none of this comes from trial exit interviews or an adverse event table for the product. Most people posting are using a topical copper product at the same time as the injection, which makes attribution impossible even within the report. The FDA adverse event material comes from the agency's 2026 BPC-157 evaluation cited on this page.
- The most consistent complaint at higher doses, roughly 500 mg and up, is loose or soft stools. A smaller number of posts describe joint or tendon discomfort starting at a few hundred milligrams; that has no counterpart in the trial record and should be read as an uncorroborated, single-source style of report rather than an established side effect.
Sources: LONGECITY's Resveratrol subforum (including a long-running 'Positive, Negative, ZERO, effect noticed?' poll thread and a dedicated side-effects thread), general web search of longevity-community and vendor commentary on dosing, form and piperine practice, and Peter Attia's public podcast and written statements. Direct access to r/longevity, r/Supplements and r/Biohackers on Reddit was not available in this research pass (Reddit pages could not be fetched and did not surface in general web search here), so those specific subreddits could not be independently checked and any overlap with the sentiment described above is inferred, not confirmed firsthand.
- Faster-feeling return from soft tissue injuries, most often tendon and shoulder complaints, reported during periods that also included rest and rehabilitation.
Sources: Peptide and bodybuilding forums, vendor testimonial pages and clinic write-ups. These are uncontrolled self-reports from people who were usually also resting and rehabilitating an injury, and they are recorded here as reports, not as findings.
- Reduced tendon and joint pain in the first few weeks, described the same way people describe BPC-157 alone.
Sources: Peptide forums including r/peptides, vendor product pages and price-comparison listings. Uncontrolled self-reports from people usually running other compounds at the same time. Recorded as reports, not evidence.
- Joint and tendon pain improving as a side effect, credited to the BPC-157.
Sources: Peptide and inflammatory bowel forums, clinic write-ups and vendor testimonial pages. Uncontrolled, usually alongside diet changes and other supplements. Reports, not evidence.
- Tendon and joint pain improving over two to six weeks.
Sources: Peptide forums including r/peptides, clinic write-ups and vendor pages. Uncontrolled self-reports. The sting comparison in particular is unblinded and the two products look different in the vial.
- Joint and tendon relief in the first weeks.
Sources: Clinic write-ups, vendor listings and peptide forums. Uncontrolled self-reports, frequently alongside other compounds. Reports, not evidence.
Why the trial record looks like this
A missing trial is usually a missing sponsor. Nobody runs a nine-figure programme on a molecule they cannot own, so the compounds with the thinnest human records are often the oldest and most freely available ones rather than the weakest. Taking BPC-157 as the example, because it states the problem most clearly:
The thin trial record is easier to read once you know who would have to pay for a thicker one. BPC-157's 15-amino-acid sequence has been in the public literature since the early 1990s, so no company can own the molecule itself. A sponsor that spent nine figures on a Phase 3 could not stop a compounding pharmacy or a research-chemical seller from offering the same peptide the week it was approved. The one company that did run human studies, Pliva in Croatia, took it through a Phase 1 and a 53-patient Phase 2 under the code PL 14736 in the early 2000s and went no further. The 2026 Pharmaceutics review reaches the same conclusion from the pharmacology side: what is missing is not evidence of biological activity but the basic pharmaceutical work, a characterised formulation, validated human pharmacokinetics and a development plan.
Thymosin beta-4 shows what the money buys. It attracted a corporate sponsor, RegeneRx, and a licensee, ReGenTree, who developed a proprietary eye-drop formulation and paid for a full programme: Phase 1, several Phase 2 trials and three Phase 3 dry eye trials that randomized 317, 601 and 700 patients. That funding bought answers rather than favourable answers. The two largest Phase 3 trials missed their co-primary endpoints. A funded programme is how you find out; an unfunded one leaves the question open, which is not the same thing as a negative answer, and also not the same thing as a positive one.
The July 2026 advisory vote sits exactly on that line. FDA's reviewers, in a May 11, 2026 memorandum, recommended against adding BPC-157 to the 503A bulks list on four grounds: the substance is not well characterised, with multiple salts and moieties sold under one common name and no United States Adopted Name or pharmacopeial monograph; nobody has studied its immunogenicity, a real question for a peptide injected repeatedly; the evidence does not support effectiveness for ulcerative colitis, the use that was nominated; and approved drugs for ulcerative colitis already exist. The committee voted 8 to 6, with one abstention, to recommend it anyway. Supporters argued that the absence of trials is not a demonstration that the peptide fails, and that a regulated compounding route is safer for people who are going to buy it regardless than the gray market they use now. Opponents, including members who said so on the record, argued that a body with no evidence of effectiveness should not be handed a legal channel. Two of FDA's four objections are about regulatory category and product quality, which a manufacturing standard could fix without a single new trial. The third is about evidence, and it is specific: nobody has tested BPC-157 for ulcerative colitis by a route anyone plans to use, and nobody has tested it in a controlled trial for the injuries most people buy it for. The recommendation is advisory. Adding a substance to the list requires FDA action, and until that happens the legal status is unchanged.
A compound appears here only when a citation on its own page states this outcome and reports a result for it; naming it is not enough. Human, animal and cell work are counted separately and never merged. Participant counts are read from the study lines and deliberately undercount. Nothing here is advice, and nothing here is a recommendation to take or to avoid anything.